Dr. Reddy`s Laboratories Ltd. - ADR

Headline results (mixed but solid momentum): - Revenue: INR 8,805 cr (~$992m), +9.8% YoY and +3% QoQ (steady top-line despite lower lenalidomide and US generics price erosion). - Profitability: EBITDA margin 26.7% (but -174 bps YoY; underlying margin ~27.5% after one-offs). - Gross margin: 54.7% (down -492 bps YoY and -223 bps QoQ) driven by lower lenalidomide, US product price erosion, and one-time inventory provisions tied to pipeline discontinuations. - PAT (equity holders): INR 1,437 cr (~$162m), +14% YoY, flat QoQ; EPS INR 17.25. - Cash: Free cash flow INR 1,046 cr (~$118m); net cash surplus ~INR 2,751 cr (~$310m).

What drove growth vs. what hurt (good vs. bad): - Good: Acquisition-led growth from consumer health care (NRT) and double-digit growth in other markets, plus favorable FX. - Bad: US generic business down ~16% YoY (to $373m) mainly from lenalidomide price/volume dynamics and broader product-specific price erosion. - Also weighing on margins: SG&A up 15% YoY (INR 2,644 cr) due to investments in acquired consumer business + branded generics; included one-time VAT liability provision (~INR 70 cr) and discontinuation-related charges.

Management outlook / margin confidence (forecast-style): - EBITDA margin recovery target: Company reaffirmed commitment to get back to ~25% EBITDA margin in FY’27, despite current margin pressure from lenalidomide decline. - Recovery thesis: “Levers” = grow base business, contain BD/costs, and focus on higher-growth/higher-margin engines like semaglutide + abatacept + biosimilars, plus productivity initiatives. - Near-term expectation: Lenalidomide tail continues but Q3 expected to have “less than Q2” (possibly last meaningful quarter or tail into Q4). - Ex-US growth confidence: Management stated they are confident of maintaining the ex-US double-digit trajectory over the next 1–2 years, backed by market-by-market drivers (Europe NRT + upcoming biosimilars; India innovation/inorganic; emerging markets oncology/injectables/biologics).